Cancer-associated Notch receptor variants lead to O-fucosylation defects that deregulate Notch signaling

Received for publication, September 8, 2022, and in revised form, October 11, 2022. Published, Papers in Press, October 18, 2022, https://doi.org/10.1016/j.jbc.2022.102616

Florian Pennarubia*, Atsuko Ito, Megumi Takeuchi, and Robert S. Haltiwanger*
From the Complex Carbohydrate Research Center, Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia, USA

Edited by Chris Whitfield

NOTCH1 is a transmembrane receptor that initiates a signaling pathway involved in embryonic development of adult tissue homeostasis. The extracellular domain of NOTCH1 is composed largely of epidermal growth factor–like repeats (EGFs), many of which can be O-fucosylated at a specific consensus sequence by protein O-fucosyltransferase 1 (POFUT1). O-fucosylation of NOTCH1 is necessary for its function. The Notch pathway is deregulated in many cancers, and alteration of POFUT1 has been reported in several cancers, but further investigation is needed to assess whether there is deregulation of the Notch pathway associated with mutations that affect O-fucosylation in cancers. Using Biomuta and COSMIC databases, we selected nine NOTCH1 variants that could cause a change in O-fucosylation of key EGFs. Mass spectral glycoproteomic site mapping was used to identify alterations in O-fucosylation of EGFs containing the mutations. Cell-based NOTCH-1 signaling assays, ligand-binding assays, and cell surface analysis were used to determine the effect of each mutation on Notch activation. Two variants led to a gain of function (GOF), six to a loss of function (LOF), and one had minimal effects. Most GOF and LOF were associated with a change in O-fucosylation. Finally, by comparing our results with known NOTCH1 alterations in cancers from which our mutations originated, we were able to establish a correlation between our results and the known GOF or LOF of NOTCH1 mutations originated, we were able to establish a correlation with known NOTCH1 alterations in cancers from which our Notch pathway and be associated with cancer processes.

The presence of an O-fucose on N1 is essential for its trafficking and function; this is particularly true for EGF8 and EGF12 in the ligand-binding domain (Fig. 1A) (23, 27–30). Cocrystallization of a portion of the N1 ligand–binding domain with its ligands DLL4 or JAG1 showed a direct interaction of O-fucose on EGF8 and EGF12 with ligand. The O-fucose on EGF12 from N1 directly contacts DLL4 and JAG1, whereas the O-fucose on EGF8 directly interacts with JAG1 (31, 32). Loss of O-fucose on EGF8 or EGF12 decreases binding of N1 to its ligands resulting in decreased associated signaling (23, 32). Elimination of O-fucose on EGF8 also led to a decrease in N1 expression at the cell surface (23). While the O-fucose on EGF9 is not directly involved in interaction with ligands, elimination of O-fucose on EGF9 also induces a decrease in ligand binding because of a decrease in expression at the cell surface (23, 33).

© 2022 THE AUTHORS. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Cancer variants affect O-fucosylation and Notch activation

Extension of O-fucose by FRINGEs, especially LFNG, also plays an important role in Notch signaling. Cell-based Notch signaling assays reveal that LFNG elongation facilitates signal induction by DLLs and inhibits signaling from JAGGED (23, 24, 33, 34). LFNG modification of the O-fucose on EGF8 and EGF12 is associated with a strong increase in ligand–receptor interaction as well as activation of the Notch pathway, especially in the case of signal induction by DLL1 (23). However, the LFNG modification of O-fucose on EGF6 and EGF36, not belonging to the binding domain, decreases the activation of the N1 pathway induced by JAG1. This decrease is not correlated with a decrease in ligand–receptor interaction, which increases in the presence of LFNG (23). The reasons associated with this process are still under investigation.

As mentioned previously, alterations of glycosyltransferases associated with O-glycosylation of N1 have been reported in cancers (15, 16). This is notably the case for POFUT1, where amplification, mutation, or upregulation has been found in hepatocellular carcinoma (35), colorectal cancer (36, 37), glioblastoma (38), and squamous cell carcinoma (39). Alteration in FRINGE expression (over, lower, or the absence of expression) has also been found in basal like cancer (40), metastatic melanoma (41), colorectal cancer (42), and claudin-low breast cancer (43). In addition, two O-fucosylation site mutations, T311P and T349P, resulting in loss of O-fucose in EGF8 and EGF9, respectively (Fig. 1A), have been reported in various cancers. Expression of these mutants compared with N1 WT in human embryonic kidney 293FT cells showed increased proliferation in cells expressing the mutant forms of the receptor (44).

Here, we searched the COSMIC (45) and Biomuta (46) databases for point mutations of the N1 receptor that produce an alteration within the O-fucose consensus sequence of EGFs included or close to the ligand-binding domain. After selecting nine mutants meeting these criteria, we compared them with WT N1 using cell-based Notch activation and ligand-binding assays. We also expressed and purified a N1 fragment containing all the EGFs in question (EGF5 to EGF14) in Chinese hamster ovary (CHO) cells in the presence or the absence of LFNG for mass spectral glycoproteomic analysis to evaluate effects of the variants on O-fucosylation. Together, these assays allowed us to demonstrate that several mutations resulted in O-fucosylation alterations leading to GOF or LOF of N1. Our results showed a correlation between the mutations

Figure 1. N1 extracellular domain and position of the mutations selected for analysis. A, representation of the extracellular part of the N1 receptor containing EGF1 to 36. EGFs indicated by circles, and selected EGFs have numbers inside. The ligand-binding domain comprising EGF8 to 12 is shown. The positions of O-fucoses and their elongation by LFNG based on Refs. (23,24). Fucose, filled red triangle; GlcNAc, filled blue square; galactose, filled yellow circle; and sialic acid, filled purple diamond. The empty red triangle represents unoccupied O-fucosylation sites. The position of each mutation is below its respective EGF. B, peptide sequence of the WT and mutant for each EGF used in this study. Position of each mutation in their respective EGF is highlighted in red. Cysteines are colored green, and O-fucosylation sites are underlined. O-fucosylation consensus sequence is shown at the bottom. EGF, epidermal growth factor–like repeat; LFNG, LUNATIC FRINGE; N1, NOTCH1.
causing GOF or LOF of N1 observed in our study and the alterations of the Notch pathway found in the corresponding cancers from which they were derived. This work shows that cancer-associated mutations in key areas of the NECD of N1 can cause significant deregulation of the Notch pathway by altering O-fucosylation of the receptor, which could be associated with the cancerous process.

Results

Identification of point mutations in cancer databases that could affect O-fucosylation of N1

According to the Biomuta and COSMIC cancer databases, there are many point mutations affecting the N1 receptor. To limit our research to mutations that could induce a change in O-fucosylation likely to affect the Notch pathway, we focused on EGFs in not only the ligand-binding domain (EGF8–12) but also on EGF6 (Fig. 1A) whose O-fucose elongation inhibits JAG1 activation (23). We found 50 mutations in this region (Table S1). We excluded 29 mutations, which resulted in loss or gain of a cysteine, which would likely cause incorrect folding of the targeted EGF and effects independent of the loss of O-glycans. The remaining 21 mutations present an amino acid change in the O-fucosylation consensus sequence (C2XXX(S/T)C3) that may affect O-fucose transfer or elongation. We selected nine of these variants based on their probability to induce an alteration of O-fucosylation. These include variants in EGF6 (G230R), EGF8 (G309R, G310R, and T349P), EGF9 (G347S and T349P), and EGF12 (D464N and A465T) (Fig. 1B). The final mutant, EGF10 N386T, creates a neo O-fucosylation site absent in the WT protein (Fig. 1B). These mutations are associated with cancers where N1 had been identified to play either an oncogenic or a tumor suppressor role. For example, the squamous cell carcinoma variants (G310R, T311P, G347S, T349P, and A465T) are associated with a Notch LOF whereas in acute lymphoblastic T-cell leukemia variants (T311P, T349P, and N386T) are associated with a GOF (4, 5). Interestingly, some mutations are present in different types of cancer where Notch is associated with both GOF or LOF (T311P and T349P) (Table S2).

EGF6 G230R: a mutation with a limited effect

The G230R mutation located two residues before the O-fucosylation site (Fig. 1B) changes a residue with no side chain, glycine, to a residue with bulky positively charged side chain, arginine. Although many residues can be found at this position in O-fucosylated EGFs, glycine is the most frequent, whereas arginine is very rarely present (47). Prior work has shown that a large residue at this position can lead to a steric clash with POFUT1, resulting in a decrease in affinity of the enzyme for the target EGF (47). Thus, this mutation could decrease O-fucosylation and/or affect LFNG elongation of EGF6, which would result in an alteration of Notch signaling. Although this EGF is not localized in the ligand-binding domain, it has been shown that modification of the O-fucose on EGF6 by LFNG inhibits induction of N1 signaling by JAG1 (23). Therefore, a change in O-fucosylation could have consequences on the ability of JAG1 to activate N1. Our mass spectrometry (MS) results showed that the G230R mutation led to a strong decrease in O-fucosylation on EGF6 (Fig. 2A). This was associated with a statistically significant decrease in the ratio of elongated O-fucose in the presence of LFNG (Fig. 2B). These O-fucosylation changes had no impact on the cell surface receptor expression since comparison of the amount of receptor between WT and G230R revealed no difference (Fig. 2C). Comparison of WT N1 and the G230R mutant in the absence of LFNG revealed no difference in Notch signaling induced by DLL1, DLL4, or JAG1 (Fig. 2, D, F, and H) although this mutant increased receptor interaction with DLL1 and JAG1 slightly (Fig. 2, J and N). The presence of LFNG induced an increase of WT N1 activation by DLL1 and DLL4 (Fig. 2, D and F) but a decrease for JAG1 (Fig. 2H). Ligand–receptor interaction increased for DLL1 and JAG1 (Fig. 2, J and N) but remained unchanged for DLL4 (Fig. 2L). Similar results were found for the G230R mutant regarding signal induction by DLL1 and DLL4 in the presence or the absence of LFNG (Fig. 2, D and F). Comparison of the LFNG/empty vector (EV) ratio, representative of the effect of LFNG, showed a lower G230R–DLL1 interaction compared with WT–DLL1 (Fig. 2K). This is most likely because of the increase in G230R–DLL1 interaction without LFNG, whereas in the presence of LFNG, this interaction remained similar to the WT–DLL1 interaction (Fig. 2F). Interestingly, the decrease of the JAG1-induced signal in the presence of LFNG was no longer present in the G230R mutant (Fig. 2H), which resulted in a significant increase of the LFNG/EV ratio in this mutant (Fig. 2F). No change in the LFNG/EV ratio was observed for G230R–JAG1 interaction compared with WT–JAG1 (Fig. 2O). The loss of JAG1-induced N1 pathway inhibition in the presence of LFNG because of decreased O-fucosylation of EGF6 is consistent with our previous results (23).

EGF8 G309R: a mutation that increased Notch signaling induced by DLL1 and DLL4

The G309R mutation is in the same position as the G230R mutation in EGF6 but targets EGF8 (Fig. 1B). Thus, this mutation may impact the ability of POFTU1 to O-fucosylate this EGF in the same way as described for EGF6. Analysis of EGF8 O-fucosylation by MS showed a small increase in unmodified peptide for the G309R mutant, significant only in the absence of LFNG (~2% and 7% for WT and G309R, respectively) (Fig. 3A). Elongation by LFNG was less effective in the presence of the G309R mutation (~95% and 65% for WT and G309R, respectively) (Fig. 3B). This lower elongation for the mutant G309R was also visible in the absence of exogenous LFNG (~15% and 9% for WT and G309R, respectively), although this trend was not significant (Fig. 3B). Moreover, the elongation profile between the WT and the G309R mutant was different, since the major elongated form in WT was the GlcNAc–Fuc disaccharide, whereas the majority of O-fucose glycans were elongated to tetrasaccharide in the mutant (Fig. 3B). No difference in cell surface expression was observed between the WT and the G309R mutant (Fig. 3C). The EGF8 G309R mutation increased
Notch pathway activation by DLL1 and DLL4 in the absence of LFNG (Fig. 3, D and F). The LFNG/EV ratio was similar between WT and G309R mutant for both ligands (Fig. 3, E and G). This increase was not found in our binding assay between the G309R mutant and DLL1 or DLL4, whose results were similar to the WT (Fig. 3, J–M). Regarding signal induction by JAG1, the only difference was the absence of signal decrease in the presence of LFNG for the G309R mutant (Fig. 3, H). Note: The negative (EV, EV + EV, and EV + LFNG) and positive (WT, WT + EV, and WT + LFNG) control data are replotted for all assays (cell surface N1, signaling DLL1, signaling DLL4, signaling JAG1, binding DLL1, binding DLL4, binding JAG1) in Figures 2–10 to allow comparison with each mutant to WT.

EGF8 G310R and T311P: two mutations strongly reducing O-fucosylation and Notch signaling

The G310R and T311P mutations affect the residue just before the O-fucosylation site and the O-fucosylation site itself, respectively (Fig. 1B). Interestingly, the G310R mutant, which
contains the O-fucosylation site, showed a large increase in unmodified peptide (≈60%) compared with the WT (≈1%) (Fig. 4A). As expected, the loss of the T311 O-fucosylation site for the T311P mutant resulted in a total absence of O-fucose (Fig. 5A). The G347S mutant also strongly reduced O-fucose modification by LFNG (Fig. 4, B). Both mutants showed a decrease in the amount of N1 on the cell surface (Figs. 4C and 5B). Both mutations induced a strong decrease in DLL1- and JAG1-induced signaling (Figs. 4, D, H, 5, C, and G) and a smaller decrease in DLL4 signaling for the G340R mutant (Fig. 4F). Despite a significant increase in DLL1-induced signal in the presence of LFNG for each mutant, this increase was smaller than for WT (Figs. 4D and 5C) as evidenced by the lower LFNG/EV ratio observed for these mutants (Figs. 4E and 5D). Both mutants showed a similar ligand-binding profile with a decrease of the N1–DLL1 interaction without modification of the LFNG/EV ratio (Figs. 4, J, K, 5, I, and J). No difference between mutants and WT was found for the N1–DLL4 or N1–JAG1 interaction (Figs. 4, L–O and 5, K–N). These results correlate with our previous study, where the use of murine N1 with a mutated EGF8 O-fucosylation site demonstrated the important role of this O-fucose in the proper function of the Notch pathway (23).

**EGF9 G347S and T349P: two mutations reducing Notch signaling to different degrees**

Like EGF6 G230R and EGF8 G309R, the G347S mutant is located two residues before the O-fucosylation site (Fig. 1B). Although this change seems less drastic than the glycan to
Cancer variants affect O-fucosylation and Notch activation

Figure 4. Effect of mutation G347S on EGF8 O-fucosylation and Notch signaling. CHO cells were cotransfected with plasmids encoding empty vector (EV) or full-length human N1 WT or G347S mutant and EV or LFNG. A and B, MS analysis. Statistical tests were performed between N1 WT + EV and G347S + EV or N1 WT + LFNG and G347S + LFNG. C, cell surface N1 quantification. D–I, cell-based coculture N1 activation assays. J–O, Notch ligand–binding assays were performed as described in the Experimental procedures section. A, quantification of the percentage of unmodified and O-fucosylated peptides. B, quantification of the percentage of the different O-fucosylated peptides (unmodified peptide excluded). Unmodified peptide (black), modified by a monosaccharide O-fucose (red), O-fucose + GlcNAc (blue), O-fucose + GlcNAc + galactose (yellow), and O-fucose + GlcNAc + galactose + sialic acid (purple). The data used to generate the EICs are available in Tables S3, S4, S9, and S10.

Our MS analysis (Fig. 7A) showed that the G347S mutation resulted in a decrease because of LFNG (Fig. 6K) resulting in a higher LFNG/EV ratio compared with WT (Fig. 6J). The interaction between JAG1 and N1 was not affected (Fig. 6, N and O).

The T349P mutation consists of a loss of the O-fucosylation site of EGF9 (Fig. 1B). The loss of O-fucosylation was found by our MS analysis (Fig. 7A) and was associated by a decrease in the expression of the N1 receptor at the cell surface (Fig. 7B). These effects were similar to those of the G347S mutant (Fig. 7, C–N) but were more drastic with a significant decrease of N1–DLL1 signaling (Fig. 7C) and binding (Fig. 7D) and a decrease of the DLL4-induced signal (Fig. 7E). As with EGF8, loss of O-fucosylase of EGF9 reduced cell surface expression of murine N1 (33). It is therefore not surprising to see the same effect for the T349P mutant deleting the O-fucosylation site, or for the G347S mutant, both resulting in a strong decrease of O-fucosyl. Unlike our previous studies where the loss of O-fucose from EGF9

arginine switch, an alteration of the O-fucosylation is possible. MS analysis showed that the G347S mutation resulted in a decrease in the proportion of O-fucosylated peptide compared with WT (≈65% and 25% for WT and G347S, respectively) (Fig. 6A). The proportion of extended O-fucose in the presence of LFNG also decreased, although this trend was not significant (Fig. 6B). This mutation reduced the expression of N1 at the cell surface (Fig. 6C). The G347S mutation also resulted in a decrease in DLL1-induced signaling (Fig. 6D) without change in the LFNG/EV ratio (Fig. 6E). The N1–DLL1 interaction was not affected in the absence of LFNG (Fig. 6F), but we observed a decrease in the LFNG/EV ratio for the G347S mutant compared with WT (Fig. 6K). The signal and interaction associated with DLL4 was similar to WT (Fig. 6, F, G, L, and M). JAG1-induced signaling was also decreased for the G347S mutant (Fig. 6H). We also observed a loss of the JAG1-induced signaling decrease because of LFNG (Fig. 6H) resulting in a higher LFNG/EV ratio compared with WT (Fig. 6I). The interaction between JAG1 and N1 was not affected (Fig. 6, N and O).
had little effect on the activation of the Notch pathway (23, 33), here, we observed a strong decrease. However, previous studies were performed by overexpressing the murine N1 receptor in NIH3T3 or human embryonic kidney 293T cell lines. It is possible that the human protein behaves differently from the murine protein. Moreover, as shown in our previous study, N1-induced signaling differs from one cell line to another (24). This probably depends on the endogenous levels of Notch receptors as well as the glycosyltransferases POFUT1 and FRINGE. Thus, the overexpression of human N1 in a CHO cell line alone could explain these differences.

**EGF10 N386T: a mutation that resulted in a neo O-fucosylation site leading to hyperactivation of the Notch pathway**

The N386T mutation introduced a neo O-fucosylation site in the ligand-binding domain of the N1 receptor (Fig. 1B). Our MS results showed that this new O-fucosylation site was about 50% occupied (Fig. 8A) and that LFNG did not modify this new O-fucose (Fig. 8, A and B). The cell surface expression of the N386T mutant was similar to WT (Fig. 8C). This mutation resulted in a significant increase in Notch signaling induced by all ligands (Fig. 8, D, F, and H). Interestingly, we observed a decrease in the LFNG/EV ratio for DLL1 likely because of the increased signal in the absence of LFNG (Fig. 8E). The N1–DLL1 interaction followed the signaling trend with an increase in interaction for the N386T mutant (Fig. 8J) associated with a decrease in LFNG/EV ratio (Fig. 8K). No difference was found for the N1–DLL4 interaction between the N386T mutant and the WT (Fig. 8L and M). Although the increase in N1–JAG1 interaction of the mutant in the absence of LFNG was not statistically significant, an increased trend was observed (Fig. 8N). This was associated with a loss of the increased binding caused by...
Cancer variants affect O-fucosylation and Notch activation

LFNG for the N386T mutant (Fig. 8N), resulting in a decrease of the LFNG/EV ratio (Fig. 8O). Thus, the addition of an O-fucose on EGF10 hyperactivated the N1 receptor. However, this hyperactivation could be caused by a change in the stoichiometry of O-fucosylation on other EGFs and not the O-fucose of EGF10 itself. Comparison of the O-fucosylation of EGF6, 8, 9, and 12 between the WT and the N386T mutant showed no difference, demonstrating that this effect was due to changes of the O-fucose on EGF10 (Fig. S1). To strengthen this hypothesis, an automated homology model was generated using the cocrystal structure between rat N1 and JAG1 (32). This model shows the EGF10 N386T O-fucose in proximity of the JAG1 ligand, suggesting the possible involvement of this O-fucose in the receptor–ligand interaction facilitating the activation of the Notch pathway (Fig. S2).

**Figure 6. Effect of mutation G347S on EGF9 O-fucosylation and Notch signaling.** CHO cells were cotransfected with plasmids encoding empty vector (EV) or full-length human N1 (WT or G347S mutant) and EV or LFNG. A and B, MS analysis. Statistical tests were performed between N1 WT + EV and G347S + EV or N1 WT + LFNG and G347S + LFNG. C, cell surface N1 quantification. D–I, cell-based coculture N1 activation assays. J–O, Notch ligand–binding assays were performed as described in the Experimental procedures section. A, quantification of the percentage of unmodified and O-fucosylated peptides. B, quantification of the percentage of the different O-fucosylated peptides (unmodified peptide excluded). Unmodified peptide (black), modified by a monosaccharide O-fucose (red), O-fucose + GlcNAc (blue), O-fucose + GlcNAc + galactose (yellow), and O-fucose + GlcNAc + galactose + sialic acid (purple). The data used to generate the EICs are available in Tables S3, S4, S13, and S14. C, mean fluorescent intensity for Notch cell surface N1 expression is shown. D–I, N1 activation assays. Relative luciferase units (RLUs) normalized to EV + EV for coculture N1 activation assays using L-cell or OP9 stably overexpressed DLL1 (D and E), DLL4 (F and G), or JAG1 (H and I) are shown. The effect of LFNG was analyzed by calculating the ratio “LFNG/EV” for DLL1 (E), DLL4 (G), and JAG1 (I). J–O, N1 ligand–binding assays. Mean fluorescence intensity for Notch ligand–binding assays using DLL1-Fc (J and K), DLL4-Fc (L and M), and JAG1-Fc (N and O) is shown. The effect of LFNG was analyzed by calculating the ratio “LFNG/EV” for DLL1 (K), DLL4 (M), and JAG1 (O). CHO Chinese hamster ovary; DLL, Delta-like ligand; EGF, epidermal growth factor; EIC, extracted ion chromatogram; JAG, JAGGED; LFNG, LUNATIC FRINGE; MS, mass spectrometry; N1, NOTCH1.

**EGF12 D464N: a mutation that increased O-fucosylation of EGF12 but reduced Notch signaling**

The D464N mutation is located two residues before the O-fucosylation site of EGF12 (Fig. 1B). The aspartate normally present at this position induces a steric clash with a POFUT1 residue reducing the affinity of the enzyme for this EGF12. Mutation of this aspartate to glycine showed a strong improvement in the affinity of POFUT1 for EGF12 (47). The presence of an asparagine for this mutant would be predicted to have limited effect unless elimination of the negative charge from the aspartate is a significant component of the effect. Interestingly, the D464N mutation significantly increased O-fucosylation of EGF12 with the percentage of unmodified peptide reduced from ~50% for the WT to <1% for the D464N mutant (Fig. 9A). Despite a tendency to increase, the percentage of elongated O-fucose for the D464N mutant remained
similar to WT in the presence or the absence of LFNG (Fig. 9B). The presence of N1 at the cell surface was not affected by this mutation (Fig. 9C). The D464N mutation caused a decrease in Notch pathway induction by DLL1 and JAG1 (Fig. 9, D and H, respectively) associated with a decrease in the LFNG/EV ratio depending on the effect of LFNG (enhancer with DLL1 or inhibitor with JAG1) (Fig. 9, E and I, respectively). DLL4-induced signaling was not affected by this mutation (Fig. 9, F and G). The DLL1 interaction was also slightly affected with a decrease of binding to the mutant (Fig. 9J). A loss of the LFNG-induced increase for JAG1 binding was also observed (Fig. 9N) associated with a decrease in the LFNG/EV ratio (Fig. 9O). The fact that the mutation caused a decrease in Notch activation by DLL1 and JAG1 was surprising since O-fucosylation of EGF12 was increased. This change in stoichiometry could have a negative effect on O-fucosylation of another EGF. We analyzed the EGF8 site, where a decrease in O-fucosylation could have explained our results. However, no difference in EGF8 O-fucosylation between the D464N mutant and the WT was observed (Fig. S3). There is also an O-glucose modification on the EGF12 peptide in addition to the O-fucose (Fig. S6E). The O-glucose was in the trisaccharide form on nearly 90% of all peptide spectral matches for the EGF12 peptide in WT and D464N mutant (Tables S3, S4, S19, and S20), suggesting that the mutation is not affecting O-glucose modifications. Another possibility would be that the aspartate residue is necessary for the ligand–receptor interaction and that its replacement by an asparagine weakens this interaction. Using automated homology model and MatchMaker of CHIMERA, we created a model for D464N mutant and superimposed it on the cocrystal structures of N1–JAG1 or N1–DLL4 (Fig. S4).
the reference structure does not suggest that the aspartate residue is directly involved in the interaction with JAG1 or DLL4. It is therefore unlikely that its replacement by an asparagine would result in a decrease in interaction responsible for our results (Fig. S4).

**EGF12 A465T: a mutation that reduced LFNG-mediated elongation and significantly reduced induction of the Notch pathway**

The A465T mutation is located one residue before the O-fucosylation site (Fig. 1B). At this position, residues with a small or nonexistent side chain such as glycine, alanine, and more rarely serine are found in POFUT1-modified EGFs (47). Thus, the presence of a threonine could disrupt the O-fucosylation of EGF12. Surprisingly, no difference in the proportion of O-fucosylation of EGF12 was observed between the WT and A465T mutant (Fig. 10A). However, the ratio of LFNG-mediated elongation O-fucose was lower in the mutant compared with the WT. In the absence of LFNG, ~12% elongation was observed for the WT and ~2% for the A465T mutant, whereas with LFNG, ~45% was observed for the WT and ~22% for the mutant (Fig. 10B). No difference between WT and A465T mutant was found for cell surface expression (Fig. 10C). This mutant induced a drastic decrease in signal induction and binding by all ligands (Fig. 10, D, E, J, and K) and to inhibit JAG1-induced signaling (Fig. 10, H and I). We created an automated homology model and

**Figure 8. Effect of mutation N386T on EGF10 O-fucosylation and Notch signaling.** CHO cells were cotransfected with plasmids encoding empty vector (EV) or full-length human N1 (WT or N386T mutant) and EV or LFNG. A and B, MS analysis. Statistical tests were performed between N1 WT + EV and N1 WT + EV or N1 WT + LFNG and N1 WT + LFNG. C, cell surface N1 quantification. D–I, cell-based coculture N1 activation assays. J–O, Notch ligand–binding assays were performed as described in the Experimental procedures section. A, quantification of the percentage of unmodified and O-fucosylated peptides. B, quantification of the percentage of the different O-fucosylated peptides (unmodified peptide excluded). Unmodified peptide (black), modified by a monosaccharide O-fucose (red), O-fucose + GlcNAc (blue), O-fucose + GlcNAc + galactose (yellow), and O-fucose + GlcNAc + galactose + sialic acid (purple). The data used to generate the EICs are available in Tables S3, S4, S17, and S18. C, mean fluorescent intensity for Notch cell surface N1 expression is shown. D–J, N1 activation assays. Relative luciferase units (RLUs) normalized to EV + EV for coculture N1 activation assays using L-cell or OP9 stably overexpressed DLL1 (D and E), DLL4 (F and G), or JAG1 (H and I) are shown. The effect of LFNG was analyzed by calculating the ratio "LFNG/EV" for DLL1 (E), DLL4 (G), and JAG1 (I). J–O, N1 ligand–binding assays. Mean fluorescent intensity for Notch ligand–binding assays using DLL1-Fc (J and K), DLL4-Fc (L and M), and JAG1-Fc (N and O) is shown. The effect of LFNG was analyzed by calculating the ratio "LFNG/EV" for DLL1 (K), DLL4 (M), and JAG1 (O). CHO, Chinese hamster ovary; DLL, Delta-like ligand; EGF, epidermal growth factor; EIC, extracted ion chromatogram; JAG, JAGGED; LFNG, LUNATIC FRINGE; MS, mass spectrometry; N1, NOTCH1.
MatchMaker of CHIMERA for the A465T mutant to check if the residue at position 465 is involved in the interaction of N1 with its ligands and superimposed it on the cocrystal structures of N1–JAG1 or N1–DLL4 (Fig. S5). The position of A465 or its mutated counterpart T465 does not appear to be directly involved in the interaction with its ligands DLL4 and JAG1.

**Discussion**

In this study, we showed that point mutations found in a variety of cancers can affect the O-fucosylation of key EGFs of N1 and deregulate activation of the Notch pathway. Among the nine selected mutations, two led to an N1 GOF (G309R and N386T), six to an N1 LOF (G310R, T311P, G347S, T349P, D464N, and A465T), and one had little or no effect (G230R). Figure 11 summarizes the results obtained for each mutant in comparison with WT for N1 cell surface expression, activation of the N1 pathway by its ligands, and EGF O-fucosylation associated with each mutation. Our results show that most of the effects of these mutations on N1 activation are consistent with the role of N1 in the cancers from which they were derived.

The T311P (EGF8) and T349P (EGF9) caused a complete loss of O-fucosylation of these EGFs leading to a decrease in N1 cell surface expression and a strong decrease in Notch activation by DLL1, DLL4, and JAG1 (Fig. 11). Thus, our results showed that these mutations induce an LOF of N1. This is consistent with the essential role of O-fucose on EGF8 in the activation of the Notch pathway (23, 27, 28, 30). The O-fucose of EGF9 seems less essential, but its loss has been associated with decreased receptor expression at the cell surface (23, 33).

Interestingly, LOF of the Notch pathway is known to be
Cancer variants affect O-fucosylation and Notch activation

Figure 10. Effect of mutation A\textsuperscript{465T} on EGF12 O-fucosylation and Notch signaling. CHO cells were cotransfected with plasmids encoding empty vector (EV) or full-length human N1 (WT or A\textsuperscript{465T} mutant) and EV or LFNG. A and B, MS analysis. Statistical tests were performed between N1 WT + EV and A\textsuperscript{465T} + EV or N1 WT + LFNG and A\textsuperscript{465T} + LFNG. C, cell surface N1 quantification. D–I, cell-based coculture N1 activation assays. J–O, Notch ligand–binding assays were performed as described in the Experimental procedures section. A, quantification of the percentage of unmodified and O-fucosylated peptides. B, quantification of the percentage of the different O-fucosylated peptides (unmodified peptide excluded). Unmodified peptide (black), modified by a monosaccharide O-fucose (red), O-fucose + GlcNAc (blue), O-fucose + GlcNAc + galactose (yellow), and O-fucose + GlcNAc + galactose + sialic acid (purple). The data used to generate the EICs are available in Tables S3, S4, S21, and S22. C, Mean fluorescent intensity for Notch cell surface N1 expression is shown. D–I, N1 activation assays. Relative luciferase units (RLUs) normalized to EV + EV for coculture N1 activation assays using L-cell or OP9 stably overexpressed DLL1 (D and E), DLL4 (F and G), or JAG1 (H and I) are shown. The effect of LFNG was analyzed by calculating the ratio "LFNG/EV" for DLL1 (E), DLL4 (G), and JAG1 (I). J–O, Notch ligand–binding assays. Mean fluorescent intensity for Notch ligand–binding assays using DLL1-Fc (J and K), DLL4-Fc (L and M), and JAG1-Fc (N and O) is shown. The effect of LFNG was analyzed by calculating the ratio "LFNG/EV" for DLL1 (K), DLL4 (M), and JAG1 (O). CHO, Chinese hamster ovary; DLL, Delta-like ligand; EGF, epidermal growth factor; EIC, extracted ion chromatogram; JAG, JAGGED; LFNG, LUNATIC FRINGE; MS, mass spectrometry; N1, NOTCH1.

prevalent in certain cancers (4), including squamous cell carcinoma of the skin (6), head and neck (7), and esophagus (8). Both the T\textsuperscript{311}P and T\textsuperscript{349}P mutations have been found in squamous cell carcinoma of head and neck with high frequency (23 and 20, respectively) (Table S2). Thus, the LOF associated with the T\textsuperscript{311}P and T\textsuperscript{349}P mutations is consistent with the role of N1 in squamous cell carcinoma.

The G\textsuperscript{310}R (EGF8) and G\textsuperscript{347}S (EGF9) showed very similar results to T\textsuperscript{311}P (EGF8) and T\textsuperscript{349}P (EGF9) mutations. Indeed, although the O-fucosylation site is still present, a strong decrease of O-fucosylation was observed. This led to a strong N1 LOF, similar to T\textsuperscript{311}P (EGF8) and T\textsuperscript{349}P (EGF9) mutants (Fig. 11). The G\textsuperscript{310}R (EGF8) and G\textsuperscript{347}S (EGF9) have also been found in squamous cell carcinoma of head and neck and in other squamous cell carcinomas for the G\textsuperscript{310}R mutation (Table S2), consistent with N1 LOF in squamous cell carcinomas.

The N\textsuperscript{386}T (EGF10) mutation created a neo O-fucosylation site within the ligand-binding domain of N1 (Fig. 1). This caused a hyperactivation of the N1 induced by DLL1, DLL4, and JAG1 (Fig. 11). Our model showed this new O-fucose in close proximity to the JAG1 ligand and could therefore be involved in enhancing ligand–receptor interactions (Fig. S2). The O-fucose of EGF10 might also play a stabilizing role for the N1 receptor, which could facilitate the conformational change necessary for its activation during the exertion of the ligand’s pulling force on N1. This N1 mutation inducing a GOF has only been found in T-cell acute lymphoblastic leukemia (Table S2), which is consistent with other studies associating N1 GOFs with this cancer (4, 11, 12).
Cancer variants affect O-fucosylation and Notch activation

| EGF | Mutation | O-fucosylation | Elongation | Cell surface | DLL1 signaling | DLL4 signaling | JAG1 signaling | Cancer |
|-----|----------|----------------|------------|--------------|----------------|----------------|----------------|--------|
| 6   | G230R    | ↓↓↓           | ↓↓         | →            | →              | →              | →              | LOF    |
| 8   | G309R    | ↓             | ↓↓         | →            | ↑              | ↑              | ↑              | GOF    |
|     | G310R    | ↑↓↓           | ↓↓         | →            | ↓              | ↓              | ↓              | LOF    |
|     | T311P    | ↓↓↓↓          | ↓↓         | →            | ↓              | ↓              | ↓              | LOF    |
| 9   | G347S    | ↓↓↓↓          | →          | →            | ↓              | ↓              | ↓              | LOF    |
|     | T349P    | ↓↓↓↓          | ↓↓         | →            | ↓              | ↓              | ↓              | LOF    |
| 10  | N386T    | ↑↑↑↑          | →          | →            | ↑↑↑↑           | ↑↑↑↑           | ↑↑↑↑           | LOF    |
| 12  | D464N    | ↑↑↑           | →          | →            | ↓              | ↓              | ↓              | GOF    |
|     | A465T    | →             | ↓↓         | →            | ↓↓↓↓           | ↓↓↓↓           | ↓↓↓↓           | LOF    |

→: No effect   ↓↓: Slight decrease   ↑↑: Slight increase   GOF: Gain Of Function
▽: Trend to decrease   ↓↓↓: Decrease   ↑↑↑: Increase   LOF: Loss Of Function
▲: Trend to increase   ↓↓↓↓: Large decrease   ↑↑↑↑: Large increase

Figure 11. Summary of the effects for each mutation and possible roles in cancer.

The G309R (EGF8) mutation caused a GOF by allowing hyperactivation of N1 induced by DLL1 and DLL4 (Fig. 11). However, the reason for this hyperactivation remains unclear. The mutation caused a loss of the disaccharide form of O-fucosylation (GlcNAcβ1,3Fucose) in the absence or the presence of LFNG (Fig. 3B). Prior studies have explored how elongation of O-fucosylation beyond the disaccharide affects N1 activity (48). Additional studies focusing on EGF8 elongation may provide additional clarification of these results. The G309R mutation has been found only once in stomach cancer (Table S2). Unfortunately, no more precise information on the nature of this cancer allows us to make a relation between the known role of Notch in this cancer and the GOF observed in our study.

The D464N (EGF12) mutation was associated with an increased O-fucosylation of EGF12 (Fig. 11). This confirmed that the relatively low abundance of O-fucosylation of EGF12 is due to the presence of the aspartate residue at position C2 + 2, which is known to induce a steric clash with tyrosine 78 of POFTU1 (47). However, the effect of increasing the O-fucosyl stoichiometry did not have the anticipated effect on N1 activity. Indeed, it is known that the loss of O-fucose from EGF12 leads to a reduction of Notch signaling (23, 29). Thus, the increase in O-fucosylation without affecting the proportion of LFNG elongation would suggest an overactivation of the pathway. However, our results showed the opposite effect: a decrease in the activation of N1 by DLL1 and JAG1 (Fig. 11). The mechanisms underlying these results remain unclear. It is possible that the role of O-fucose on EGF12 is clearly dependent on its stoichiometry and that too much or too little O-fucose alters signaling. The mutation may slightly modify the structure of EGF12, which would slightly shift the position of the O-fucosylated threonine side chain. Since the O-fucose of EGF12 interacts directly with its ligands (31, 32), even a slight change in its position could alter this interaction and decrease their ability to induce Notch signaling. In any case, this mutation leads to an N1 LOF. Unfortunately, the details of the cancers where these mutations have been found are not precise enough to allow us to correlate our results with any known deregulation of the Notch pathway (Table S2).

The A465T (EGF12) mutation resulted in a drastic decrease of N1 activation by all ligands. O-fucosylation was not modified, but the elongation of O-fucose was lower in the mutant with or without LFNG (Figs. 10 and 11). This suggests that even a small amount of O-fucose extension on EGF12 by a Fringe could have a large effect on N1 activation. Alternatively, as with the D464N mutation, A465T could lead to a conformational change in the side chain of the O-fucosylated threonine leading to a reduced interaction with N1 ligands. It is interesting to note that the A465T mutation induced a larger decrease in N1 activation or ligand binding compared with the D464N mutant (Fig. 11). Being closer to the O-fucosylated threonine, A465T could generate a larger displacement of the O-fucosylated threonine compared with the D464N mutant. This would lead to a stronger decrease of the interaction and the activation of the Notch pathway. Our results show that the A465T mutation is associated with an N1 LOF. This mutation was mostly found in squamous cell carcinoma (Table S2), where a prevalence of N1 LOF has been demonstrated (4).

The G230R (EGF6) mutation caused a strong decrease in O-fucosylation and O-fucose elongation but had very little effect on Notch signaling. The only visible effect was a loss of Notch inhibition induced by JAG1 in the presence of LFNG (Fig. 11). This result is consistent with previous studies where loss of O-fucosylation of EGF6 following mutation of the O-fucosylated threonine to valine showed similar results (23). This mutation would result in an N1 GOF in cases where JAG1 was the predominant activating ligand, and either LFNG or MFNG were expressed in the N1-expressing cells. Further studies are necessary to determine whether this is the case in the cancers listed in Table S2.

Although most of our signaling and binding assay results are explained by changes in glycosylation, some of them do not correlate or do not fully correlate with our mass spectral data. This is particularly the case for mutants G309R, D464N, and A465T. It cannot be excluded that the use of a truncated form of the N1 receptor (EGF5–14) with only five O-fucosylation sites presents a different O-glycosylation profile than the full-length form, which has 20 sites (17 of which are occupied) (23).
Cancer variants affect O-fucosylation and Notch activation

In conclusion, this study shows that mutations within the O-fucose consensus sequence of N1 EGFs can induce GOF or LOF being involved in the cancer process. It is very likely that similar mutations in other Notch receptors, especially NOTCH2, might have similar effects (33). It would also be interesting to study the effect of point mutations within the consensus sequences of other types of O-glycosylation (e.g., O-glucose and O-GlcNAc) (18) of N1 found in some cancers. Overall, the essential role of O-glycosylation in the Notch pathway requires further investigation of their involvement in the cancer process.

Experimental procedures

Plasmid constructs

The plasmid encoding full-length human N1 (pcDNA3.1) was generously provided by Dr Steven Blacklow (Harvard) (49). Plasmids encoding human N1 EGF5–14 WT and mutants with C-terminal Myc-His6 tags (pSecTag2/HygroC; Invitrogen) was constructed by amplifying the ORF with HindIII or XhoI restriction enzyme sites for subcloning, respectively, into a plasmid using polyethyleneimine (with a polyethyleneimine/DNA ratio of 4/1). After 4 h, the media are removed, the cells are washed with 1× PBS, and complete media are added. After 24 h, cells are washed with 1× PBS and then 1 ml of 1× PBS is added. The cells are slowly detached by pipetting. After washing cells with washing buffer (Hank’s balanced salt solution), the cells were incubated with 100 nM DLL1-Fc (R&D Systems), JAG1-Fc (R&D Systems), or DLL4-Fc (R&D Systems) and anti-Fc phycocerythrin (PE)–conjugated antihuman antibody (Jackson ImmunoResearch; 1:20 dilution) or anti-Fc PE–conjugated antimouse antibody (Fisher Scientific; 1:20 dilution) in binding buffer on ice for 1 h (Hank’s balanced salt solution containing 1% bovine calf serum, 0.05% azide, and 1 mM CaCl2). For cell surface hN1 detection, washed cells were incubated with PE antihuman Notch 1 antibody (BioLegend; 1:20 dilution) for 1 h. After washing cells with washing buffer, binding was determined and analyzed using an Accuri C6 flow cytometer. Ten thousand cells were gated for RFP expression, and PE intensity of the RFP-expressing cells was determined.

Production of N1 EGF5–14 WT and mutants in the absence of LFNG

Production of N1 EGF5–14 WT was done in Pro5 CHO cells as previously described (24). Briefly, after approximately 5 days of production, media were collected centrifuged at 4000g for 15 min, and then syringe filtered with a 0.45 µm syringe filter. NaCl and imidazole were added to a final concentration of 1 M and 20 mM, respectively. For purification, a 150 µl nick–nitritolactiic acid agarose (Qiagen) bead volume (300 µl 50% slurry) was used. Wash buffer consisted of 1 M NaCl and 20 mM imidazole in 1× Tris-buffered saline. Proteins were eluted using 250 mM imidazole in 1× Tris-buffered saline.

Glycoproteomic mass spectral analysis of hN1 EGF5–14

Glycoproteomic analysis was performed as described previously (24). Briefly, 10 µl of purified protein was denatured and reduced using 10 µl of reducing buffer containing 8 M urea, 400 mM ammonium bicarbonate, and 10 mM Tris(2-carboxyethyl)phosphine (chymotrypsin digestion) or 8 M urea, 50 mM Tris–HCl, pH 8, and 10 mM Tris(2-carboxyethyl) phosphine (V8 digestion) at 50 °C for 5 min. Alkylation was performed at room temperature in the dark with 100 mM iodoacetamide in 50 mM Tris–HCl for 30 min. About 45 µl of mass spectrometric grade water (chymotrypsin digestion) or 250 mM diammonium phosphate solution (V8 digestion) were added to each sample. Chymotrypsin (50 ng) or V8 (50 ng) was added, and samples were incubated in a 37 °C water bath for 1 h (chymotrypsin) or 20 h (V8). Next, 7 µl of 5% formic acid were added, and samples were desalted with Millipore C18 Zip Tip Pipette Tips. After elution in 50% acetonitrile and 0.1% acetic acid, samples were diluted to 25% acetonitrile and 0.1% formic acid. Approximately 10 ng of each sample were injected on a Q-Exactive Plus Orbitrap mass spectrometer (Thermo Fisher) with an Easy nano-LC HPLC system with a C18 EasySpray PepMap RSLC C18 column (50 µm × 15 cm;
Thermo Fisher Scientific). A 30 min binary gradient solvent system (solvent A: 5% acetonitrile and 0.1% formic acid in water and solvent B: 80% acetonitrile and 0.1% formic acid in water) with a constant flow of 300 nl/min was used. Positive polarity mode was used with an m/z range of 400 to 2000 at a resolution of 70,000 and automatic gain control set to 1 × 10⁶. Higher energy collisional dissociation-tandem MS was used on the top 10 precursor ions in each full scan (collision energy set to 27%, 1 × 10⁵ gain control, isolation window m/z 1.2, dynamic exclusion enabled, and 17,500 fragment resolution). PMI-Byonic (version 2.10.5; Protein Metrics) was used to identify glycopeptides. Fixed modifications: carbamidomethyl +57.021464 at C. Variable modifications: oxidation +15.994915 at M, H, W, N, and D; deamidated +0.984016 at F, N, Q, and R. Glycoforms searched: unmodified peptide, modified peptide with O-fucose, modified peptide with HexNAc, modified peptide with O-fucose, HexNAc, and hexose, or modified peptide with O-fucose, HexNAc, hexose, and NeuAc. All these glycoforms were searched for in association with the presence or the absence of O-hexose, O-hexose and pentose, or O-hexose, pentose, and pentose. Precursor and fragment mass tolerance was set to 20 ppm. Four missed cleavages were allowed. The extracellular part of the human N1 receptor containing EGF5 to 14 (P46531) was used as a database. Xcalibur Qual Browser (version 2.0.3) was used to generate extracted ion chromatograms for all identified O-fucosylated peptides. For each peptide, the area under the curve was calculated for each peak corresponding to searched glycoforms. Relative abundance was calculated by comparing the area under the curve for a single glycoform to the total area under the curve for all searched glycoforms of a specific peptide. MS/MS spectra for each glycopeptide analyzed are shown in Fig. S6.

Automated homology models for human N1 N³⁸⁶T, D⁴⁶⁴N, and A⁴⁶⁵T

Homology models were generated by using Swiss–model server for human N1 N³⁸⁶T, D⁴⁶⁴N, and A⁴⁶⁵T using structure of complex of N1 (EGF8–12) bound to Jagged1 (N-EGF3) (Protein Data Bank [PDB] code: 5UK5) or complex of N1 (EGF11–13) bound to Delta-like 4 (N-EGF2) (PDB code: 4XLW) as a reference template. Using Matchmaker of CHIMERA, these models were superimposed with the reference template (PDB codes: 5UK5 or 4XLW) to replace N1 WT by its mutated counterpart. Finally, a shortened version of the PDB file 5UK5 containing EGF12 with O-fucose was overlaid on EGF10 of the N³⁸⁶T mutant using Matchmaker of CHIMERA to allow the positioning of an O-fucose on this EGF.

Statistical analysis

All experiments were performed in biological triplicates or more, and results were reported as the means ± SD. Statistical significance was determined using unpaired t test. Significance levels: (***) for p < 0.005, (**) for p < 0.001, and (*) for p < 0.05.

Cancer variants affect O-fucosylation and Notch activation

The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (52) partner repository (https://www.ebi.ac.uk/pride) accessed on August 26, 2022) with the dataset identifier PXD036345. Table S23 provides a description of the files in the PRIDE repository.

Supporting information—This article contains supporting information.

Acknowledgments—We thank Dr Kelvin Luther for reading and commenting on the article and other members of the Haltiwanger laboratory for helpful discussions.

Author contributions—F. P. and R. S. H. conceptualization; F. P. investigation; A. I. and M. T. resources; F. P. data curation; F. P. writing—original draft; F. P., A. I., and R. S. H. writing—review & editing; R. S. H. supervision; R. S. H. project administration; R. S. H. funding acquisition.

Funding and additional information—Supported by funding from the National Institutes of Health (grant no.: GM061126; to R. S. H.) and the Georgia Research Alliance (to R. S. H.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: CHO, Chinese hamster ovary; DLL, Delta-like ligand; EGF, epidermal growth factor; EGF11, EGF12, EGF13, EGF14, –fucose was overlaid –fucose on this –fucose was overlaid –fucose, Hex–fucose, pentose, or pentose, or –fucose, pentose, and pentose. Precursor and fragment mass tolerance was set to 20 ppm. Four missed cleavages were allowed. The extracellular part of the human N1 receptor containing EGF5 to 14 (P46531) was used as a database. Xcalibur Qual Browser (version 2.0.3) was used to generate extracted ion chromatograms for all identified O-fucosylated peptides. For each peptide, the area under the curve was calculated for each peak corresponding to searched glycoforms. Relative abundance was calculated by comparing the area under the curve for a single glycoform to the total area under the curve for all searched glycoforms of a specific peptide. MS/MS spectra for each glycopeptide analyzed are shown in Fig. S6.

Automated homology models for human N1 N³⁸⁶T, D⁴⁶⁴N, and A⁴⁶⁵T

Homology models were generated by using Swiss–model server for human N1 N³⁸⁶T, D⁴⁶⁴N, and A⁴⁶⁵T using structure of complex of N1 (EGF8–12) bound to Jagged1 (N-EGF3) (Protein Data Bank [PDB] code: 5UK5) or complex of N1 (EGF11–13) bound to Delta-like 4 (N-EGF2) (PDB code: 4XLW) as a reference template. Using Matchmaker of CHIMERA, these models were superimposed with the reference template (PDB codes: 5UK5 or 4XLW) to replace N1 WT by its mutated counterpart. Finally, a shortened version of the PDB file 5UK5 containing EGF12 with O-fucose was overlaid on EGF10 of the N³⁸⁶T mutant using Matchmaker of CHIMERA to allow the positioning of an O-fucose on this EGF.

Statistical analysis

All experiments were performed in biological triplicates or more, and results were reported as the means ± SD. Statistical significance was determined using unpaired t test. Significance levels: (***) for p < 0.005, (**) for p < 0.001, and (*) for p < 0.05.

References

1. Artavanis-Tsakonas, S. (1999) Notch signaling: cell fate control and signal integration in development. Science 284, 770–776
2. Pennarubia, F., and Haltiwanger, R. S. (2022) Glycans, Notch signaling and development. In Reference Module in Life Sciences. Elsevier, Amsterdam. B9780128216187000000
3. Kopan, R., and Ilagan, M. X. (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216–233
4. Aster, J. C., Pear, W. S., and Blacklow, S. C. (2017) The varied roles of Notch in cancer. Annu. Rev. Pathol. Mech. Dis. 12, 245–275
5. Miele, L., Artavanis-Tsakonas, S., eds. (2018) Targeting Notch in Cancer: From the Fruit Fly to the Clinic. Springer New York, New York, NY. https://doi.org/10.1007/978-1-4939-8859-4
6. Wang, N. J., Sanborn, Z., Arnett, K. L., Bayston, L. J., Liao, W., Proby, C. M., et al. (2011) Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. U. S. A. 108, 17761–17766
7. Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., et al. (2011) Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154–1157
8. Agrawal, N., Liao, Y., Bettegowda, C., Hutless, S. M., Wang, Y., David, S., et al. (2012) Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2, 899–905
9. Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525
Cancer variants affect O-fucosylation and Notch activation

10. Cancer Genome Atlas Research Network, Brat, D. J., Verhaak, R. G. W., Aldape, K. D., Yung, W. K. A., Salama, S. R., et al. (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. *N. Engl. J. Med.* 372, 2481–2498

11. Pancewicz, J., Taylor, J. M., Datta, A., Baydoun, H. H., Waldmann, T. A., Hermine, O., et al. (2010) Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. *Proc. Natl. Acad. Sci. U. S. A.* 107, 16619–16624

12. Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-izarra, C., et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science* 306, 269–271

13. Kridel, R., Meissner, B., Rogic, S., Boyle, M., Telenius, A., Woolcock, B., et al. (2012) Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. *Blood* 119, 1963–1971

14. Robinson, D. R., Kalyana-Sundaram, S., Wu, Y.-M., Shankar, S., Cao, X., Shankar, S., et al. (2009) Mammalian Notch1 is modulated by an unusual form of O-fucosylation. *J. Biol. Chem.* 284, 1646–1651

15. Matsumoto, K., Luther, K. B., and Haltiwanger, R. S. (2021) Diseases related to Notch glycosylation. *Mol. Aspects Med.* 79, 100938

16. Wang, W., Okajima, T., and Takeuchi, H. (2022) Notch signalling is responsible for the viability of Notch1[12f/12f] mice. *BMC Dev. Biol.* 19, 19

20. Takeuchi, H., Yu, H., Hosh, H., Takeuchi, M., Ito, A., Li, H., et al. (2017) O-Glycosylation modulates the stability of epidermal growth factor-like repeats and thereby regulates Notch trafficking. *J. Biol. Chem.* 292, 15964–15973

21. Luca, V. C., Jude, K. M., Pierce, N. W., Nachury, M. V., Fischer, S., and Garcia, K. C. (2015) Structural basis for Notch1 engagement of delta-like 4. *Science* 347, 847–853

22. Luca, V. C., Kim, B. C., Ge, C., Kakuda, S., Wu, D., Reine-Peikar, M., et al. (2017) Notch-Jagged complex structure implicates a catch bond in tuning ligand sensitivity. *Science* 355, 1320–1324

23. Kakuda, S., LoPilato, R. K., Ito, A., and Haltiwanger, R. S. (2020) Canonical Notch ligands and Fringes have distinct effects on NOTCH1 and NOTCH2. *J. Biol. Chem.* 295, 14710–14722

24. Moloney, D. J., Panin, V. M., Johnston, S. H., Chen, J., Shao, L., Wilson, R., et al. (2000) Fringe is a glycosyltransferase that modifies Notch. *Nature* 406, 369–375

25. Ma, L., Dong, P., Liu, L., Gao, Q., Duan, M., Zhang, S., et al. (2016) Overexpression of protein O-fucosyltransferase 1 accelerates hepatocellular carcinoma progression via the Notch signaling pathway. *Biochem. Biophys. Res. Commun.* 473, 503–510

26. Chabanais, I., Labrousse, F., Chaunavel, A., Gernot, A., and Maftah, A. (2018) POFUT1 as a promising novel biomarker of colorectal cancer. *Cancers* 10, 411

27. Deschuyter, M., Pennarubia, F., Pinault, E., Legardinier, S., and Maftah, A. (2020) Functional characterization of POFUT1 variants associated with colorectal cancer. *Cancers* 12, 1430

28. Kroes, R. A., Dawson, G., and Moskal, J. R. (2007) Focused microarray analysis of glyco-gene expression in human glialbastomas. *J. Neurochem.* 103, 14–24

29. Yokota, S., Ogawara, K., Kimura, R., Shimizu, F., Baba, T., Minakawa, Y., et al. (2013) Protein O-fucosyltransferase 1: a potential diagnostic marker and therapeutic target for human oral cancer. *Int. J. Oncol.* 43, 1864–1870

30. Xu, K., Usary, J., Kousis, P. C., Prat, A., Wang, D.-Y., Adams, J. R., et al. (2012) Lunatic fringe deficiency cooperates with the Met/Cavin-3 gene amnic to induce basal-like breast cancer. *Cancer Cell* 21, 626–641

31. Del Castillo Velasco-Herrera, M., van der Weyden, L., Nsengimana, J., Speak, A. O., Sjöberg, M. K., Bishop, D. T., et al. (2018) Comparative genomics reveals that loss of lunatic fringe (LFNG) promotes melanoma metastasis. *Mol. Oncol.* 12, 239–255

32. López-Arríbilaga, E., Rodilla, V., Colomer, C., Vert, A., Shelton, A., Cheng, J. H., et al. (2018) Manic Fringe deficiency imposes jagged1 addiction to intestinal tumor cells. *Nat. Commun.* 9, 2992

33. Zhang, S., Chung, W.-C., Wu, G., Egan, S. E., Miele, L., and Xu, K. (2015) Manic fringe promotes a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction. *Cancer Res.* 75, 1936–1943

34. Larose, H., Prokoph, N., Matthews, J. D., Schlederer, M., Högl, S., Alsulami, F. A., et al. (2020) Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. *Haematologica* 106, 1693–1704

35. Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., et al. (2019) Cosmic: the catalogue of somatic mutations in cancer. *Nucl. Acids Res.* 47, D941–D947

36. Dingerdissen, H. M., Torcivia-Rodriguez, J., Hu, Y., Chang, T.-C., Mazumder, R., and Kahsay, R. (2018) BioMuta and BioXpress: mutation and expression knowledgebases for cancer biomarker discovery. *Nucl. Acids Res.* 46, D1128–D1136

37. Li, Z., Han, K., Pak, J. E., Satkunarajah, M., Zhou, D., and Rini, J. M. (2017) Recognition of EGF-like domains by the notch-modifying O-fucosyltransferase POFUT1. *Nat. Chem. Biol.* 13, 757–763

38. Hou, X., Tashima, Y., and Stanley, P. (2012) Galactose differentially modulates lunatic and manic fringe effects on delta1-induced NOTCH signaling. *J. Biol. Chem.* 287, 474–483
Cancer variants affect O-fucosylation and Notch activation

49. McMillan, B. J., Zimmerman, B., Egan, E. D., Lofgren, M., Xu, X., Hesser, A., et al. (2017) Structure of human POFUT1, its requirement in ligand-independent oncogenic Notch signaling, and functional effects of Dowling-Degos mutations. *Glycobiology* 27, 777–786

50. Johnston, S. H., Rauskolb, C., Wilson, R., Prabhakaran, B., Irvine, K. D., and Vogt, T. F. (1997) A family of mammalian Fringe genes implicated in boundary determination and the Notch pathway. *Development* 124, 2245–2254

51. Matsumoto, K., Kumar, V., Varshney, S., Nairn, A. V., Ito, A., Pennarubia, F., et al. (2022) Fringe GlcNAc-transferases differentially extend O-fucose on endogenous NOTCH1 in mouse activated T cells. *J. Biol. Chem.* 298, 102064

52. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., et al. (2019) The PRIDE database and related tools and resources in 2019: improving support for quantification data. *Nucl. Acids Res.* 47, D442–D450